<DOC>
	<DOCNO>NCT00657137</DOCNO>
	<brief_summary>This study compare anti-tumor efficacy apricoxib lapatinib/capecitabine placebo lapatinib/capecitabine measure time disease progression evaluate urinary PGE-M measurement baseline COX-2 expression tumor tissue IHC surrogate selection criterion patient benefit future treatment apricoxib .</brief_summary>
	<brief_title>APRiCOT-B : Study Evaluate Apricoxib Combination With Lapatinib Capecitabine Treatment HER2/Neu+ Breast Cancer ( TP2001-202 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Females pathologically determine locally advanced metastatic human epidermal growth factor receptor 2 positive ( HER2/neu+ ) breast cancer Have progress treatment chemotherapy include taxane trastuzumab Must measurable disease RECIST ECOG PS 0,1 , 2 MUGA scan echocardiogram result show left ventricular ejection fraction great equal 50 % Radiation therapy within 2 week , chemotherapy within 3 week , noncytoxic investigational agent within 4 week initiate study treatment Evidence New York Heart Association class III great cardiac disease History MI , stroke , ventricular arrhythmia , symptomatic conduction abnormality History congenital QT prolongation Concurrent severe uncontrolled medical disease Symptomatic central nervous system metastases Pregnant nursing woman Hypersensitivity intolerance apricoxib , lapatinib , capecitabine , 5FU , sulfonamide , aspirin , NSAIDs Severe renal insufficiency History upper GI bleeding , ulceration , perforation Concurrent use potent CYP3A4 inhibitor CYP3A4 inducer Prior treatment capecitabine Patients antiarrhythmic treatment Prior lapatinib therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HER2/neu positive</keyword>
	<keyword>locally advanced metastatic</keyword>
</DOC>